| Engineering toxins for 21st century therapies. | |
| | |
MedLine Citation:
|
PMID: 21382174 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
'Engineering Toxins for 21st Century Therapies' (9-10 September 2010) was part of the Royal Society International Seminar series held at the Kavli International Centre, UK. Participants were assembled from a range of disciplines (academic, industry, regulatory, public health) to discuss the future potential of toxin-based therapies. The meeting explored how the current structural and mechanistic knowledge of toxins could be used to engineer future toxin-based therapies. To date, significant progress has been made in the design of novel recombinant biologics based on domains of natural toxins, engineered to exhibit advantageous properties. The meeting concluded, firstly that future product development vitally required the appropriate combination of creativity and innovation that can come from the academic, biotechnology and pharma sectors. Second, that continued investigation into understanding the basic science of the toxins and their targets was essential in order to develop new opportunities for the existing products and to create new products with enhanced properties. Finally, it was concluded that the clinical potential for development of novel biologics based on toxin domains was evident. |
| | |
Authors:
|
John A Chaddock; K Ravi Acharya |
Related Documents
:
|
8873634 - The cma code of ethics: more room for reflection. 12501724 - Personal meaning and ethics in engineering. 16186204 - Commentary: toward a unified theory of personal and professional ethics. 15253574 - Obtaining informed consent in an egyptian research study. 8873634 - The cma code of ethics: more room for reflection. 19490584 - Novel insights into proteomic technologies and their clinical perspective. |
Publication Detail:
|
Type: Journal Article Date: 2011-02-03 |
Journal Detail:
|
Title: The FEBS journal Volume: 278 ISSN: 1742-4658 ISO Abbreviation: FEBS J. Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-03-08 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101229646 Medline TA: FEBS J Country: England |
Other Details:
|
Languages: eng Pagination: 899-904 Citation Subset: IM |
Copyright Information:
|
© 2011 The Authors Journal compilation © 2011 FEBS. |
Affiliation:
|
Syntaxin Limited, Abingdon, Oxon, UK Department of Biology and Biochemistry, University of Bath, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A case-control study on platelet reactivity in patients with coronary stent thrombosis.
Next Document: The Effect of Vitamin D3 and Ketoconazole Combination on VDR-mediated P-gp Expression and Function i...